Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Artios Pharma Ltd.
Headquarters: Cambridge, United Kingdom
Website: http://www.artiospharma.com/...
Year Founded: 2016
Status: Private
BioCentury | May 2, 2024
Deals
Novartis gains α-emitter, radioligand platform via $1B Mariana takeout
Largest upfront M&A payment for a preclinical biotech in three years
BioCentury | Feb 8, 2024
Management Tracks
New chair, CFO for I-Mab as part of U.S. push
Plus: Artios hires Silverstein as CFO and updates from Astellas, atai, Cartography, Corvus and Helio
BioCentury | Sep 28, 2023
Management Tracks
Expanded role for Gaito at J.P. Morgan
Plus: Peptone hires a new CSO, names Gritstone’s Allen chair, and updates from Foresite, OncoC4, Sibylla, Cell-Easy and Photocure
BioCentury | Aug 4, 2023
Finance
Biotechs that could enter the IPO queue as crossovers await liquidity
Among dozens of companies that raised crossover cash before markets turned sour, some may soon have what it takes to go public
BioCentury | Dec 1, 2022
Politics, Policy & Law
U.K. biotechs risk losing millions in R&D tax credit changes
As bear market grinds on, proposed changes could see U.K. life sciences sector lose up to £800m a year
BioCentury | May 5, 2022
Management Tracks
Legault named Egle chairman
Plus Tom Hughes becomes chairman of Totus, and updates from Immunicum, Kbio and more
BioCentury | Apr 2, 2022
Emerging Company Profile
Varsity: tapping academia for cancer combination partners
Cycle sister company Varsity aims to combat resistance to first-line cancer therapies with repurposed agents in-licensed from academics
BioCentury | Jul 28, 2021
Deals
July 27 Quick Takes: Three times and it’s still charming for AbbVie, Calico
Light demand for Candel IPO, plus Keytruda, AC Immune, Relmada, Regeneron-AstraZeneca
BioCentury | Jun 18, 2021
Translation in Brief
Blocking POLQ for PARP inhibitor-resistant cancer; plus Innovative Molecules’ herpes simplex therapy
BioCentury’s roundup of translational news
BioCentury | Apr 21, 2021
Product Development
Synthetic lethality’s second wind
The thinking goes beyond the binary paradigm of target plus mutation
Items per page:
1 - 10 of 37